#241

COMPLETE

Collector:	Web Link 1 (Web Link)
Started:	Wednesday, August 12, 2026 1:11:43 AM
Last Modified:	Wednesday, August 12, 2026 1:24:57 AM
Time Spent:	00:13:13
IP Address:	184.144.76.79

Page 2: Part 1

Q1

Title of activity

Practice Changing Evidence: Systematic Reviews of the Year

Q2

Date of activity

October 17, 2026

Q3

What is your role in the CPD activity? (Select all that apply)

Speaker

Q4

What's your practice type?

Academic Practice

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Any direct financial payments including receipt of honoraria

Respondent skipped this question

Q7

Membership on advisory boards or speakers' bureaus

Respondent skipped this question

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s) (separate with commas)	**CAAIF, CSACI, GPER, CDC, Joint Task Force on Practice Parameters, OMA-MOH, Ontario Ministries, CIHR**
Description of relationship(s)	**Grant funding to institution**

Q9

Patents on a drug, product or device

Respondent skipped this question

Q10

All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity

Respondent skipped this question

Page 3: Part 2: To be completed by presenters only

Q11

I intend to use trade names during my presentation.Note: Only generic names should be used whenever possible. If trade names are used, they should be accompanied by the generic name.

No

Q12

I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication).Note: You must declare all off-label use to the audience during your presentation.

Yes (please provide a brief description or rationale):
Only those accepted as common in clinical practice and that have rigorous evidence supporting their efficacy and safety

Q13

If you answered "Yes" to the previous question, are the medications recommended manufactured by companies you have received funding from?

N/A

Q14

I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.

Yes

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

Yes

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Derek

Q17

Last Name:

Chu

Q18

Respondent skipped this question

Gender Pronouns - How would you like us to address you?

Q19

I confirm that the above information is accurate and complete.

Please review and check the items below.